Research on treating disease with medication. Covers psychedelics, combination cancer therapy, opioid treatment in pregnancy, and personalized guidelines.
Researchers have developed a new therapeutic agent from Brazilian lapacho tree bark that targets acute myeloid leukemia cells while minimizing toxic effects on healthy cells. The compound is attached to an antibody that binds specifically to cancer cells, delivering the drug directly to its target.
Researchers at Stowers Institute for Medical Research have developed a precise model for the stinging organelle of the starlet sea anemone, revealing its complex architecture and firing mechanism. The findings could lead to beneficial applications in medicine, including microscopic therapeutic delivery devices.
Researchers at Baylor College of Medicine have identified a potential more effective treatment for HER2 mutant metastatic breast cancer, poziotinib. The drug reduced tumor growth and multi-organ metastasis in laboratory tests and animal models.
A population-based study found that patients with estrogen receptor-positive breast cancer who experienced hot flashes while on adjuvant hormone therapy had worse outcomes and a higher risk of early treatment discontinuation. The study suggests that managing side effects may not be enough to prevent treatment discontinuation, highlight...
Researchers identified a three-gene signature in multiple myeloma tumors that predicts a positive response to selinexor-based therapy. The discovery could improve patient selection for targeted agents and expand the use of the drug into patients who haven't failed other therapies.
A new study by Vertice Pharma confirms that drinking coffee does not affect the absorption of a liquid formulation of levothyroxine. The research suggests that patients can take their medication with coffee without worrying about reduced absorption. This finding could lead to more flexibility in dosing and improved patient outcomes.
A novel targeted radionuclide alpha therapy, AC-NM600, has been shown to achieve significantly better outcomes than its corresponding beta therapy in treating metastatic castration-resistant prostate cancer. The study demonstrated slowed tumor growth and improved overall survival.
Researchers found thalidomide to be an effective treatment for severe arteriovenous malformations (AVMs), reducing symptoms and improving quality of life in patients. The study showed a striking reduction in symptoms, with some patients experiencing complete cure after treatment.
Researchers at the University of Cincinnati are studying how lipids help fortify lung cancer cells and if targeting them can lead to better outcomes. The team discovered that lipids play a crucial role in cancer cell growth, membrane fortification, and energy production.
A novel BRAF inhibitor, C1a, has been developed to cross the blood-brain barrier and treat melanoma brain metastasis. The study found that C1a triggered robust responses in patient-derived models and outperformed approved BRAF inhibitors, achieving significant increases in survival rates.
A new study found that circulating tumor DNA can identify stage II colon cancer patients who benefit from chemotherapy, sparing others the need for treatment. The study showed reduced use of chemotherapy without compromising survival rates.
A new cell therapy has been developed to target and eliminate leukemia stem cells that cause disease relapse. The treatment uses genetically engineered T cells with a chimeric antigen receptor that recognizes specific markers on these cancer cells.
Researchers have identified new biomarkers to detect non-small cell lung cancer in its early stages through a blood test, offering improved survival chances. The approach can also identify potential drug resistance, allowing clinicians to choose alternative treatment options.
Researchers at the University of Chicago's Pritzker School of Molecular Engineering have developed a version of interleukin-12 that is activated only when it reaches a tumor, reducing side effects. The new 'masked' molecule has shown promising results in eliminating cancer cells and outperforming existing immune therapies.
Researchers found that inhibiting caspase 11 reduced inflammation, tissue injury and blood clots in lung tissue of infected mice. This suggests potential therapeutic targets for treating severe COVID-19 symptoms.
A retrospective analysis of 7,000 patients found pulse oximeter devices overestimated blood oxygen levels in non-White patients, delaying treatment eligibility recognition. The study suggests that biases in pulse oximeter accuracy disproportionately affect minority communities.
Researchers found that severe asthma patients produce growth factors that block corticosteroids from working, leading to frequent breathing problems. This discovery may lead to new treatments targeting these growth factors to improve outcomes for patients with severe asthma.
Research found that hypomethylating agents (HMAs) activated the oncofetal protein SALL4 in up to 40% of patients with MDS, resulting in poor patient survival. This activation is linked to demethylation and upregulation of oncogenes, suggesting a need for additional combination therapy.
A new study found that crown-like structures surrounding breast tumors in overweight and obese patients can hinder their response to therapy. Researchers identified a potential molecular biomarker, CD32B, which is associated with poorer treatment outcomes.
Researchers at Keck School of Medicine of USC are testing the efficacy of 3K3A-APC as a cerebroprotectant to reduce brain bleeds in acute ischemic stroke patients. The experimental drug has shown promising results in Phase 2 clinical trials, reducing incidence of brain hemorrhage by nearly 20%.
Researchers at the University of Virginia Health System have made important discoveries on the crucial role of malnutrition in global tuberculosis, highlighting how gut infections impair treatment outcomes. A new funding partnership will train Tanzanian postdoctoral researchers to work specifically on this intersection.
Daily gabapentin treatment restored fine motor functions in mice's upper extremities and continued to show functional improvements even after treatment was stopped. The drug blocks the activity of a protein that hinders re-growth of axons, enabling post-stroke central nervous system repair to progress in a coordinated way.
Researchers found that polypharmacy and sedative drugs are associated with an increased risk of long-term care needs certification among older adults. The study highlights the need for public health initiatives to reduce high-risk prescribing practices, which may lead to a decrease in disability risk.
Researchers at Penn Medicine have developed an imaging agent that detects cancer cells in real-time during biopsies, offering promise for earlier and more accurate diagnoses. The technology, known as NIR-nCLE, uses a combination of near-infrared tracers and confocal laser endomicroscopy to identify microscopic cancer cells.
Researchers at MedUni Vienna identified five distinct subtypes of small cell lung cancer, each responding differently to therapies. High ASCL1 expression is linked to poor survival, while high POU2F3 expression correlates with better outcomes and sensitivity to standard chemotherapeutics.
A team of scientists led by Professor Barbara Pierscionek has made significant progress in developing an anti-cataract drug. Lab trials showed improvement in refractive index profiles and lens opacity in 61% and 46% of cases, respectively.
A recent study analyzed a large database of bladder cancer patients and found that fewer than half had been tested for the relevant gene mutation or received erdafitinib treatment, despite its proven efficacy. The research highlights significant barriers to treatment, including obstacles in testing and education for healthcare providers.
A large study has found six predictors that can help determine the optimal lithium dose for patients with bipolar disorder. The predictors include age, sex, kidney function, and medication use. The researchers hope to develop a digital app to aid psychiatrists in finding the right dose.
Researchers have developed a process to convert non-neuronal cells into functioning neurons that can take up residence in the brain and restore capacities undermined by Parkinson's destruction of dopaminergic cells. In a proof-of-concept study, one group of experimentally engineered cells performs optimally in terms of survival, growth...
A new drug called abemaciclib has been shown to halt the growth of recurring brain tumors in patients with aggressive meningiomas. The treatment targets a common molecular pathway that enables cells to divide rapidly and come back after surgery, allowing researchers to predict recurrence more accurately.
Researchers at H. Lee Moffitt Cancer Center & Research Institute have identified key factors impacting the effectiveness of adaptive therapy in cancer treatment. The study found that spatial organization and competition between drug-resistant cells play a crucial role in determining the success of adaptive therapy.
Researchers have discovered a way to suppress a specific protein that promotes resistance to drugs commonly used to treat AML patients. This breakthrough has the potential to revolutionize treatment and prolong survival for those affected by the disease.
A team of international researchers created digital models of disease interactions to identify key proteins and signaling cascades in seasonal allergies. They found that inhibiting PDGF-BB protein was more effective than existing treatments, suggesting a potential breakthrough in personalized medicine.
Researchers developed a droplet-based microfluidic technology to produce micro-organospheres from cancer patient biopsies within an hour. These miniature tumors retain the original microenvironment and can be used for testing many drug conditions, showing almost perfect correlation with actual clinical treatment outcomes.
Researchers at the University of Missouri are applying AI to analyze protein dynamics, identifying potential target sites for new drug therapies. The approach can simulate protein changes related to conditions like cancer, enhancing the chances of successful therapies.
Researchers created patient-derived models of brain metastases that recapitulate human disseminated disease, reflecting clinical manifestations and biological characteristics. These models can be used to test therapeutic value of different treatments and explore new approaches tailored to each patient.
The joint guide provides a framework for establishing theranostic centers globally, focusing on safety protocols and operational procedures. It highlights best practices for radiation protection, storage, administration, and other topics to improve patient care.
The University at Buffalo is developing new treatments for ovarian cancer by targeting the apelin receptor. Ovarian cancer cells rely on lipids for energy and survival, making this a promising therapeutic target.
Researchers at Tokyo University of Science identify brain regions and signaling pathways involved in fear extinction via delta receptor activation. The study suggests a potential therapeutic agent for post-traumatic stress disorders by suppressing fearful memories.
A new study estimates the national economic burden of PTSD at $232.2 billion for 2018, with civilians accounting for 82% of the total costs. The study calls for increased awareness, effective therapies, and expanded evidence-based strategies to reduce the clinical and economic burden of PTSD.
A NIH-funded study found that patients with retinal vein occlusion experience significant visual acuity gains, but require long-term monitoring and treatment. After five years, many participants retained an average of three lines of improvement in their visual acuity.
Researchers are developing radioconjugate drugs that combine radiation with a tumor-targeting agent to selectively kill cancer cells. Two approved drugs, Lutathera and Pluvicto, demonstrate the potential of this therapy, which could change the future of cancer treatment.
A study has identified a new protein, Creb-binding protein (CBP), as a prognostic marker for above-average patient survival in HPV-positive head and neck carcinoma. CBP inhibitors are being developed as targeted therapies that can improve quality of life by reducing side effects associated with conventional chemotherapy or radiotherapy.
A new study found that Black kidney transplant recipients exhibit a faster clearance rate of tacrolimus, an immunosuppressive drug. The study suggests that considering both sex and race when dosing tacrolimus may reduce adverse effects and enhance transplant outcomes.
Researchers have found that treating prostate cancer cells with novel CDK8 and CDK19 inhibitors reduces their potential to migrate into surrounding structures. This suggests a promising approach to overcome resistance against anti-androgenic therapy, offering new therapeutic options for patients with advanced disease.
The TTUHSC's C. Patrick Reynolds has received a $1.34 million CPRIT grant to investigate updating the clinical risk stratification scale for neuroblastoma and rhabdomyosarcoma, two childhood cancers in need of improved therapies.
Researchers at Rutgers University propose a new approach to COVID-19 vaccine testing by combining conventional and challenge trials. This parallel approach, called Combining Conventional and Challenge trials (CCC), aims to facilitate faster and more accurate vaccine assessment and more effective pandemic response.
Researchers evaluated monoclonal antibody administration methods and their impact on COVID-19 hospitalization and death rates. The study found no significant difference in effectiveness between injection and intravenous administration, suggesting that injection could expand outpatient treatment capacity.
Finnish researchers created a comprehensive map of molecular interactions between 58 human receptor tyrosine kinases (RTKs), revealing key insights into their functions and roles in disease. The study's findings can aid understanding of diseases linked to abnormal RTK activity, particularly cancer.
A randomized clinical trial found that participants treated at non-stigmatizing 'accessible care' centers were nearly three times more likely to be cured of hepatitis C than those referred out to local clinicians. The study suggests that expanding and supporting accessible care models could help eliminate the disease.
Recent studies published in the Journal of Pharmaceutical Analysis have found applications of nanotechnology in medicine, drug research, and environmental protection. Researchers developed nanodots made of carbon using natural polysaccharides from mushrooms to detect chromium, and created nanozymes that could be used to detect drug con...
Researchers have discovered a potential new treatment for glioblastoma, which targets 'kinase' proteins to limit tumour growth and improve existing chemotherapeutic drugs. This breakthrough therapy may provide hope for patients with aggressive brain tumours, offering a more effective and sustainable approach to treatment.
A large US study confirms a strong link between ED medications and vision problems, including an 85% increased risk of developing serious eye conditions. Regular use of Viagra, Cialis, Levitra, or Stendra may lead to side effects such as age-related macular degeneration (AMD) and retinal vein occlusion (RVO).
A recent study published in Molecular Therapy Nucleic Acids found that the molecule urocortin-2 may regulate recovery processes after a heart attack by modulating miR-29a. Treatment with urocortin-2 could favor patient recovery by regulating apoptosis and fibrosis.
Scientists create nanoparticles coated in mannose to block production of scar-promoting protein in lung cells. The treatment holds promise for preventing severe lung scarring disease.
A new study found that customized digital alerts via an electronic health record system significantly increased the number of guideline-directed medications prescribed for heart failure patients. The alerts improved medication use by over a quarter of patients, translating to one medication addition per every 14 alerts received.
Researchers at the University of Eastern Finland have developed a novel nuclear microRNA, miR-466c, that regulates vascular endothelial growth factor A (VEGFA) expression in response to hypoxia. The drug has commercial relevance for treating ischemic cardiovascular disease by increasing VEGFA levels.
A Johns Hopkins-led study published in New England Journal of Medicine found that convalescent plasma from recovered COVID-19 patients can effectively treat outpatients, with a 54% reduced need for hospitalization. The therapy's effectiveness increases with earlier administration within five days after diagnosis.
Levi A. Garraway is being honored for his groundbreaking contributions to cancer research, including the identification of melanoma genes and development of precision oncology approaches. He has also championed parallel sequencing as a definitive approach to tumor genomic profiling, revolutionizing cancer treatment strategies.
Researchers at Penn Medicine have developed a new approach to alter immune cells for CAR T cell therapy in just 24 hours, cutting manufacturing time from nine to 14 days. This could make the therapy more cost-effective and accessible to more patients.